Biotech & Pharma AlertsGet biotech and pharma industry news delivered straight to your inbox the moment it's released.
One perfectly positioned biotech Don’s going to tell you about today is close to hitting the crucial $1 billion threshold.
It hasn’t happened yet, but when it does, they’ll have done it faster than the likes of Apple or Google.
And if you’re finding out about it now, you’re just in time because the setup looks very promising.
But you’ll have to act fast, and grab the shares before Wall Street finds out about it….
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
One of the starkest lessons of the global novel coronavirus pandemic is the need for medicine to start looking at existing drugs and procedures in a new way.
We've already seen the benefits of such an approach. The discovery that remdesivir and dexamethasone – an antiviral and a steroid – could both help save severely ill COVID-19 patients' lives springs right to mind.
But adapting the old to fight the new isn't just limited to drugs. Existing medical technology ("medtech") is being used in entirely new ways, or in situations that would've been unthinkable just 10 or 12 months ago.
That's why today I want to talk to you about two compelling companies behind a radical, aggressive therapy that can deliver a "one-two punch" for coronavirus patients who might've otherwise died… Full Story
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
It might be too early to call it "a light at the end of the tunnel," but the quest for a novel coronavirus vaccine has entered a new, perhaps decisive phase.
We knew fairly quickly after the pandemic exploded that life in most places could never be as it was until an effective vaccine or therapy was produced.
And now we're beginning to get a picture – tentative, to be sure – of when and how that might happen.
Infectious disease expert Dr. Anthony Fauci has said he expects FDA emergency approval of some kind of vaccine by November or December of this year.
Taking it a step further, both Bill Gates and CDC Director Dr. Robert Redfield have indicated the logistics of vaccine distribution will mean life "will start to return to normal" by second and third quarters of 2021, or roughly 18 months after the social and economic devastation of this crisis started.
That seems like an awfully long time, and of course it is, but, as of now, the current "speed record" holder in the vaccine stakes belongs to Merck & Co. Inc.'s Mumpsvax.
And when I say "speed record," understand that it took nearly five years to develop Mumpsvax back in the 1960s.
For us to have an effective vaccine – any vaccine – by the end of 2020, or a little over a year since the disease emerged, would be a breathtaking, unparalleled scientific achievement.
There are dozens upon dozens of different vaccines and therapies being researched all over the world, all in different stages. The market, however, is paying the closest attention to just a few.
Aside from AstraZeneca Plc. in the United Kingdom, there are two frontrunner candidates in the United States, both in late, phase 3 clinical trials.
There's Moderna Inc., whose shares have soared as high as 400%, and Pfizer Inc., which has been rather more subdued this year, but whose vaccine candidate is a favorite in some circles for the first emergency approval.
With that said, the stock I'm going to name might not be first, but it may very well be the best… Full Story
With that said, the stock I'm going to name might not be first, but it may very well be the best...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
2020 has not been the most exciting year for IPOs.
While the big coronavirus crash in March prompted a lot of investors to buy stocks on the cheap,.
the uncertainty has kept many companies from going public with their shares.
Of course, for every rule there are exceptions.
Biotech IPOs have been as popular as ever amid the pandemic, and for good reason too: There’s money out there for companies who can help end the pandemic.
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
"Lead, follow, or get out of the way."
This is one of those well-known aphorisms that's been around forever – though its originator is unknown.
Truth be told, it doesn't matter who said it first. It's a great bit of advice.
Especially as we interpret it.
In our investment work here at Money Morning, we always seek to lead Wall Street and the rest of the packrat investment crowd.
We never follow, especially since "the crowd" tends to be indecisive, late to the gun – or flat out wrong.
And we always get out of the way – sidestepping the dust-rising thump that's an inevitable result of the miscues and sins of the Wall Street Goliath.
It's a simple formula. And a successful one.
And it's the reason we keep outperforming "the crowd."
Like the 2,067% gain on biotech Galapagos NV, the very first stock I recommended on the very first day I published my Member-based service, Private Briefing, back in August 2011.
My readers also pulled down peak gains of more than 2,892% in Nvidia, 2,828% in Advanced Micro Devices, 818% in biotech buyout Pharmacyclics, and more.
Today, I've decided to share my latest insight on one of my big biotech winners with Money Morning readers because the opportunity is too good to keep to ourselves. And since my colleague Michael Robinson recently talked about 2020's record-crushing biotech IPOs, it's the perfect time to share this.
The company I'm showing you today is essential to biotech stocks. It's a "biotech-enabler" that's zoomed 1,755% since I first told my readers about it back in June 2013.
In 2013, it was trading at $8.14.
It closed July 30 at $151.25 – not long after Investor's Business Daily said the stock had entered a "Buy Zone."
True, but where were they seven years and 1,755% ago?
Of course, what's important now is what comes next – and it's clear this stock's run isn't over… Full Story
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
I'll come right out and say it: Every investor should be doing their level best to position themselves at the epicenter of biotechnology – pharmaceuticals – right now.
These stocks are leading a soaring stock market, particularly the NASDAQ Composite, which is at all-time highs. Of the index's 10 biggest gainers at midday yesterday, half were biotechs.
Obviously, the race to find a vaccine or even a proven therapy for the novel coronavirus pandemic is a huge driver of the profits here. My paid subscribers recently got the chance to book 375% gains on half of one of our vaccine research plays, and took 70% in profits on another.
But there's much more going on.
The sheer amount and volume of capital pouring into this sector like a firehose – it's nothing short of breathtaking.
I'm going to show you my favorite, low-risk way to tap that immense growth.
But first, you have to see some of these numbers… Full Story
But first, you have to see some of these numbers...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Biotech stocks find themselves in a very interesting, and potentially very profitable, situation right now.
It's widely believed by public health officials that we can't return to "normal" until scientists discover a coronavirus vaccine that can be widely distributed.
That's the primary reason why the Trump administration launched "Operation Warp Speed."
The U.S. government is investing billions of dollars in biotech companies to develop a COVID-19 vaccine as quickly as possible – so the world can return to normal.
But not all biotech stocks are worth buying right now.
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
This tech stock is checking all of Chris Johnson's boxes when it comes to the best stock to trade this earnings season…
As companies everywhere settle into a post-COVID virtual reality, this company could be a leading provider of tech solutions.
They just crushed earnings expectations for the fourth quarter in a row, and according to Chris, the profit potential won't stop there.
See the full details in this, the latest from Fast Profits with Money Morning...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
The three biggest Big Pharma "blockbuster" medicines of all time target high cholesterol (Lipitor), inflammatory diseases (Humira), and digestive afflictions (Nexium) and have pulled in a combined $350 billion – and counting.
But what about people suffering from rare diseases like cystic fibrosis, pancreatic cancer, and so on?
Here in America, Washington understands the need for these "orphan drugs" targeting rare diseases, which is why the "Orphan Drug Act of 1983" offers a seven-year window of tax reductions and the exclusive right to market a drug for a particular rare disease.
To date, more than 600 orphan drugs have been approved by the FDA.
And the global market for orphan drugs targeting rare diseases is growing at double the rate of the non-orphan market.
But more needs to be done. And that "more" will create a massive investment portal – provided you pick the best-positioned companies.
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Everyday when I wake up, I read The Wall Street Journal.
See, a large part of my day involves looking for new ideas to invest in.
Whether it is reading the Journal, a recent earnings transcript or a company's website, I am always on the lookout for my next big idea.
But four times a year, I get to read a set of reports that are chock full of ideas.
Start the conversation